在临床试验中,Onco-Innovations将PNKP抑制剂的产量扩大到1560克和2公斤. Onco-Innovations scaled up PNKP inhibitor production to 1,560 grams and 2 kg for clinical trials.

科创新公司与达尔顿制药服务公司合作,推进了其PNKP抑制剂的生产规模扩大,实现了1560克前体A83的合成,并开始2公斤非GMP活性药物成分A83B4C63的生产. Onco-Innovations has advanced the manufacturing scale-up of its PNKP inhibitor in collaboration with Dalton Pharma Services, achieving a 1,560-gram synthesis of precursor A83 and initiating a 2 kg non-GMP production of the active pharmaceutical ingredient A83B4C63. 这项工作支持IND启用研究和未来的临床试验,加强多伦多工厂的过程稳定性和制造准备. This work supports IND-enabling studies and future clinical trials, strengthening process robustness and manufacturing readiness at a Toronto facility. 公司还扩大了与MCS的市场沟通合作,以提高企业知名度. The company also extended its market communications engagement with MCS for corporate visibility.